import into the United States of any drug by, with the assistance of, or at the direction of Mr. Kumar during his period of debarment is a prohibited act.

Grace R. Graham,

Deputy Commissioner for Policy, Legislation, and International Affairs.

[FR Doc. 2026–19419 Filed 9–22–26; 8:45 am]

BILLING CODE 4164–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Neurological Disorders and Stroke; Notice of Closed Meeting

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of a meeting of the Board of Scientific Counselors, National Institute of Neurological Disorders and Stroke.

The meeting will be closed to the public as indicated below in accordance with the provisions set forth in section 552b(c)(6), Title 5 U.S.C., as amended for the review, discussion, and evaluation of individual intramural programs and projects conducted by the National Institute of Neurological Disorders and Stroke, including consideration of personnel qualifications and performance, and the competence of individual investigators, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Board of Scientific Counselors, National Institute of Neurological Disorders and Stroke.

Date: October 29–30, 2026.

Time: October 29, 2026, 9:30 a.m. to 8:00 p.m.

Agenda: To review and evaluate to review and evaluate personnel qualifications and performance, and competence of individual investigators.

Address: National Institute of Neurological Disorders and Stroke, National Institutes of Health, Porter Neuroscience Research Center, Building 35A, 35 Convent Drive, Room GF–149, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Time: October 30, 2026, 10:00 a.m. to 3:00 p.m.

Agenda: To review and evaluate to review and evaluate personnel qualifications and performance, and competence of individual investigators.

Address: National Institute of Neurological Disorders and Stroke, National Institutes of Health, Porter Neuroscience Research Center, Building 35A, 35 Convent Drive, Room GF–149, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Jeffrey S. Diamond, Ph.D., Acting Scientific Director, c/o Caren Collins, Program Analyst, Division of Intramural Research, NINDS, Office of the Scientific Director, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Porter Neuroscience Research Center, Building 35A, 35 Convent Drive, Room GF–149, Bethesda, MD 20892, 301–435–1896, *diamondj@ninds.nih.gov; collinsca@ninds.nih.gov*.

Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person.

(Catalogue of Federal Domestic Assistance Program Nos. 93.853, Extramural Research Programs in the Neurosciences and Neurological Disorders; 93.854, Biological Basis Research in the Neurosciences, National Institutes of Health, HHS)

Dated: September 21, 2026.

Rosalind M. Niamke,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2026–19457 Filed 9–22–26; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Center for Scientific Review; Amended Notice of Meeting

Notice is hereby given of a change in the meeting of the Musculoskeletal, Oral and Skin Sciences Integrated Review Group; Oral, Dental and Craniofacial Sciences Study Section, October 15, 2026, 08:00 a.m. to October 16, 2026, 07:00 p.m., National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 which was published in the **Federal Register** on August 31, 2026, Doc. 2026–17687, 91 FR 55890.

This meeting is being amended to change the start of meeting to 9.30 a.m. instead of 8.00 a.m. on October 15, 2026. Meeting dates will stay the same October 15–16, 2026. The meeting is closed to the public.

Dated: September 21, 2026.

Margaret N. Vardanian,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2026–19459 Filed 9–22–26; 8:45 am]

BILLING CODE 4167–05–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

SUMMARY: The inventions listed below are owned by an agency of the U.S. Government and are available for licensing to achieve expeditious commercialization of results of federally-funded research for the benefit of the public health.

FOR FURTHER INFORMATION CONTACT: Licensing information may be obtained by emailing the indicated licensing contact at the National Heart, Lung, and Blood, Office of Technology Transfer and Development, 31 Center Drive, Room 4A25, MSC2479, Bethesda, MD 20892–2479; *NHLBI_TechTransfer@mail.nih.gov.* A signed Confidential Disclosure Agreement may be required to receive any unpublished information.

SUPPLEMENTARY INFORMATION: Technology description follows.

Hematopoietic Stem Cell and Progenitor Cell Transplantation Therapy Technology

Available for licensing and commercial development are patent rights covering recombinant bivalent (bi) single-chain variable fragment (scFV) minibody targeting the cMPL receptor on HSPCs, fused with diphtheria toxin (DT) truncated at residue 390 (DT390-biscFV(cMPL)) that can be used to deplete HSPCs with increased safety in patients undergoing HSPC transplantation. Patient conditioning is a critical initial step in hematopoietic stem and progenitor cell (HSPC) transplantation procedures, especially for leukemia patients, that enables marrow engraftment of infused cells. Conditioning regimens have traditionally been achieved by delivering cytotoxic doses of chemotherapeutic agents and radiation. However, these regimens are associated with significant morbidity and mortality and cannot be used safely in elderly or subjects with comorbidities.

Potential Commercial Applications:

- Use as a novel conditioning regimen with increased safety for patients undergoing transplantation.
- Investigational tool to study hematopoietic stem and progenitor cell (HSPC) biology and improve gene therapy and cell therapy.

Competitive Advantages:

• transplantation efficacy.

• Limits chemotherapeutic cytotoxicity.

• Better penetrants into deep tissue, such as bone marrow niche.

• Short half-life allowing rapid clearance before cell re-infusion.

• More efficiently dimerizes cMPL receptor than the whole IgG.

Development Stage:

• Preclinical.

• In vivo data available (animal).

Related Publications:

• Araki D, Hong SG, Linde N, Fisk B, Redekar N, Salisbury-Ruf C, Krouse A, Engels T, Golomb J, Dagur P, Panicker SR, Kanthi Y, Magnani DM, Wang Z, Larochelle A. cMPL-based purification and depletion of human hematopoietic stem cells: implications for pretransplant conditioning. Blood. 2025 Jun 19;145(25):2978–2991. doi: *10.1182/blood.2024024636*. PMID: 40009502; PMCID: PMC12226764.

Intellectual Property: HHS Ref. No.: E–188–2021–0.

• U.S. Provisional Application No. 63/251,883 filed October 4, 2022.

• PCT Application No. PCT/US22/77326 filed September 30, 2022.

• U.S. Application No. 18/688,899 filed March 4, 2024.

• European Patent Application No. 22813001.9 filed March 8, 2024.

• Israel Patent Application No. 311590 filed March 19, 2024.

• China Patent Application No. 202280065162.6 filed March 26, 2024.

Collaborative Research Opportunity: The National Heart, Lung, and Blood Institute is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. For collaboration opportunities, please contact Dr. Vincent Kolesnitchenko, 301–594–4115 or *vk5q@nih.gov* and reference E–188–2021–0.

Licensing Contact: Vincent Kolesnitchenko, Ph.D.; 301–594–4115; *vk5q@nih.gov*.

''This Notice is in accordance with 37 CFR 404.4 Authority to grant licenses.''

Dated: September 21, 2026.

Vincent A. Kolesnitchenko,

Senior Technology Transfer Manager, National Heart, Lung, and Blood Institute, Office of Technology Transfer and Development.

[FR Doc. 2026–19431 Filed 9–22–26; 8:45 am]

BILLING CODE 4167–05–P

DEPARTMENT OF HOMELAND SECURITY

U.S. Customs and Border Protection

Electronic Export Manifest for Truck Cargo Test

AGENCY: U.S. Customs and Border Protection, DHS.

ACTION: General notice.

SUMMARY: This document announces that U.S. Customs and Border Protection (CBP) will conduct an Automated Commercial Environment (ACE) Electronic Export Manifest (EEM) for Truck Cargo Test. The ACE EEM for Truck Cargo Test is a voluntary test in which truck export participants agree to the submission of certain limited export manifest data electronically at least 24 hours prior to departure from the United States to a foreign destination to then be complemented by the complete export manifest filing no later than two (2) hours prior to arrival at the final port of export. This notice provides a description of the test, sets forth eligibility requirements for participation, and invites public comment on any aspect of the test.

DATES: The test will begin on October 23, 2026 and will run for approximately two years, subject to any extension, modification, or early termination as announced in the **Federal Register**. CBP is accepting applications for participation in this planned test until CBP has received applications from nine parties that meet all test participant requirements. Comments concerning this notice and all aspects of the announced test may be submitted at any time during the test period.

ADDRESSES: Applications to participate in the Electronic Export Manifest for Truck Cargo Test must be submitted via email to: *cbptruckexportmanifest@cbp.dhs.gov*.

In the subject line of the email, please use ''Electronic Export Manifest for Truck Cargo Test Application.'' Written comments concerning program, policy, and technical issues may also be submitted via email *tocbptruckexportmanifest@cbp.dhs.gov*. In the subject line of the email, please use ''Comment on Electronic Export Manifest for Truck Cargo Test.''

FOR FURTHER INFORMATION CONTACT: David Garcia, Program Manager, Outbound Enforcement and Policy Branch, Office of Field Operations, CBP, via email at *cbptruckexportmanifest@cbp.dhs.gov*.

SUPPLEMENTARY INFORMATION:

I. Background

The National Customs Automation Program

The National Customs Automation Program (NCAP) was established in Subtitle B of Title VI—Customs Modernization, in the North American Free Trade Agreement Implementation Act (Pub. L. 103–182, 107 Stat. 2057, Dec. 8, 1993) (Customs Modernization Act) (19 U.S.C. 1411–15). Through NCAP, the initial thrust of customs modernization was on trade compliance and the development of the Automated Commercial Environment (ACE). ACE is an automated and electronic system for commercial trade processing which is intended to streamline business processes, facilitate growth in trade, ensure cargo security, and foster participation in global commerce, while ensuring compliance with U.S. laws and regulations and reducing costs for U.S. Customs and Border Protection (CBP) and all of its communities of interest. The ability to meet these objectives depends on successfully modernizing CBP's business functions and the information technology that supports those functions. CBP's modernization efforts are accomplished through phased releases of ACE component functionality, which was designed to replace the paper function, or to create a new function. Each release begins with a test and ends with mandatory use of the new ACE feature. Each release builds on previous releases and sets the foundation for subsequent releases.

Authorization for the Test

The Customs Modernization Act provides the Commissioner of CBP with the authority to conduct limited test programs or procedures designed to evaluate planned components of the NCAP. The test described in this notice is authorized pursuant to the Customs Modernization Act, *see* 19 U.S.C. 1411–1415, and section 101.9(b) of title 19 of the Code of Federal Regulations (19 CFR 101.9(b)), which provides for the testing of NCAP programs or procedures. As provided in 19 CFR 101.9(b), for purposes of conducting an NCAP test, the Commissioner of CBP may impose requirements different from those specified in the CBP regulations.

International Trade Data System (ITDS)

This test is also in furtherance of the International Trade Data System (ITDS) key initiatives, set forth in section 405 of the Security and Accountability for Every Port Act of 2006 (Pub. L. 109–347, 120 Stat. 1884, Oct. 13, 2006) (SAFE Port Act) (19 U.S.C. 1411(d)). The stated purpose of ITDS is to eliminate